Pure Global: Brazil's Cyber Shock - Navigating ANVISA's New MedTech Rules

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for foreign manufacturers. We explore the specific documentation now required and what this means for anyone trying to enter Latin America's largest market. This move signals a major shift in the region's regulatory philosophy, moving away from simple adoption of global standards towards hyper-local requirements tied to national laws like the LGPD. We analyze the immediate impact on companies with pending applications, using a real-world example of a European company whose market entry is now stalled, facing unforeseen costs and significant delays. Key Questions Answered: - What specific cybersecurity evidence does ANVISA now demand beyond FDA or CE Mark documentation? - How does Brazil's data privacy law (LGPD) create unique compliance risks for MedTech manufacturers? - Why is a global cybersecurity plan now insufficient for a successful Brazilian market submission? - What are the most common pitfalls leading to deficiency letters from ANVISA for SaMD products? - Are other LATAM countries like Mexico and Colombia expected to follow Brazil's lead? - How can you turn this complex new regulatory hurdle into a competitive advantage? - What should be included in a post-market surveillance plan to satisfy these new requirements? Navigating sudden regulatory shifts is what we do best. Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI tools to streamline your market access. Whether it's developing a new regulatory strategy, compiling technical dossiers, or acting as your local representative, we ensure you stay ahead of the curve. Don't let regulatory surprises derail your LATAM expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.